KQ Labs’ Post

Exciting news from the Collision conference in Toronto! 🎉 Four Canadian tech startups—Heylist, Vosyn, Pok Pok, and Ability Biologics—have announced new funding rounds. Heylist raised $1.6M to connect nano-influencers with brands, Vosyn secured $2.2M for its real-time language translation AI, Ability Biologics boosted its seed round to $18M USD for cancer therapy research, and Pok Pok closed a $6M Series A to expand its educational app. 🌟 What do you think about these innovative startups and their missions? Share your thoughts in the comments below! ⬇️💬 #technology #startup #techstartups #technews #funding

Can John Maraganore's 'Next-Generation RNAi' Startup Revolutionize Biotech?" Biotech industry veteran, @JMaraganore is back on the scene with a new venture that promises to redefine RNA interference (RNAi). Armed with an impressive $135m in initial funding, Maraganore intends to build on the success of his previous endeavor and push forward into uncharted territories of biotech innovation. What could this mean for disease prevention and treatment? And how might such advancements influence the broader scientific community? Read up on it here 👉 https://lnkd.in/dpN9rQ9x Ignite Corporate Innovation! 🚀 From AI solutions to automation, we provide technical prowess that drives growth. Book your meeting now: https://lnkd.in/dbQkg2ac Join +160k corporate decision-makers, investors & innovative founders. Enhance operations & create new revenue streams through collaboration and startup access. Transcend your innovation strategies into successful ventures! #RNAinterference #Biotechnology #JohnMaraganore #Startup #InnovationStrategy #CorporateInnovation #AIforGrowth #InvestorsCommunity #DiseasePrevention #NextGenTherapeutics

Can John Maraganore's 'Next-Generation RNAi' Startup Revolutionize Biotech?" Biotech industry veteran, @JMaraganore is back on the scene with a new venture that promises to redefine RNA interference (RNAi). Armed with an impressive $135m in initial funding, Maraganore intends to build on the success of his previous endeavor and push forward into uncharted territories of biotech innovation. What could this mean for disease prevention and treatment? And how might such advancements influence the broader scientific community? Read up on it here 👉 https://lnkd.in/drE4thXY Ignite Corporate Innovation! 🚀 From AI solutions to automation, we provide technical prowess that drives growth. Book your meeting now: https://lnkd.in/dMu5TpiV Join +160k corporate decision-makers, investors & innovative founders. Enhance operations & create new revenue streams through collaboration and startup access. Transcend your innovation strategies into successful ventures! #RNAinterference #Biotechnology #JohnMaraganore #Startup #InnovationStrategy #CorporateInnovation #AIforGrowth #InvestorsCommunity #DiseasePrevention #NextGenTherapeutics

Can John Maraganore's 'Next-Generation RNAi' Startup Revolutionize Biotech?" Biotech industry veteran, @JMaraganore is back on the scene with a new venture that promises to redefine RNA interference (RNAi). Armed with an impressive $135m in initial funding, Maraganore intends to build on the success of his previous endeavor and push forward into uncharted territories of biotech innovation. What could this mean for disease prevention and treatment? And how might such advancements influence the broader scientific community? Read up on it here 👉 https://lnkd.in/dpN9rQ9x Ignite Corporate Innovation! 🚀 From AI solutions to automation, we provide technical prowess that drives growth. Book your meeting now: https://lnkd.in/dbQkg2ac Join +160k corporate decision-makers, investors & innovative founders. Enhance operations & create new revenue streams through collaboration and startup access. Transcend your innovation strategies into successful ventures! #RNAinterference #Biotechnology #JohnMaraganore #Startup #InnovationStrategy #CorporateInnovation #AIforGrowth #InvestorsCommunity #DiseasePrevention #NextGenTherapeutics

Can John Maraganore's 'Next-Generation RNAi' Startup Revolutionize Biotech?" Biotech industry veteran, @JMaraganore is back on the scene with a new venture that promises to redefine RNA interference (RNAi). Armed with an impressive $135m in initial funding, Maraganore intends to build on the success of his previous endeavor and push forward into uncharted territories of biotech innovation. What could this mean for disease prevention and treatment? And how might such advancements influence the broader scientific community? Read up on it here 👉 https://lnkd.in/dpN9rQ9x Ignite Corporate Innovation! 🚀 From AI solutions to automation, we provide technical prowess that drives growth. Book your meeting now: https://lnkd.in/dbQkg2ac Join +160k corporate decision-makers, investors & innovative founders. Enhance operations & create new revenue streams through collaboration and startup access. Transcend your innovation strategies into successful ventures! #RNAinterference #Biotechnology #JohnMaraganore #Startup #InnovationStrategy #CorporateInnovation #AIforGrowth #InvestorsCommunity #DiseasePrevention #NextGenTherapeutics

🚀 Keen to learn more about what pharma companies seek in their partnerships with startups?  Apply now for KQ Labs Cohort 7: https://shorturl.at/Wh3DX At KQ Labs, we connect founders with a curated network of investors, industry experts, and pharma partners. For instance, a key feature of our programme is our Office Hours, where we facilitate valuable conversations between our founders and top pharmaceutical companies. During these Office Hours, founders have the opportunity to… 💪 Learn about what leading pharma companies are currently seeking in terms of technology and products. 🪴 Receive personalised feedback on their startup's potential and alignment with industry needs. 📈 Understand emerging trends and challenges in the pharma sector directly from those on the front lines. 💡 Build relationships with key stakeholders that can open doors for future collaborations and partnerships. Don't miss out on this unique opportunity to propel your startup forward. Apply now and become part of KQ Labs Cohort 7! Proudly part of The Francis Crick Institute, with sponsorship from Cancer Research Horizons for one cancer-focused venture. #HealthTech #Startups #Innovation #Pharma

Exciting Funding Updates in the Startup World! 🚀 🔍 Dive into the latest key startup fundraising rounds from this week: 1️⃣ Ideally: Secures $5.5m funding led by Icehouse Ventures and OIF Ventures, boosting its impactful customer insights platform. 2️⃣ Cartherics Pty Ltd: Bags $15m to advance trials of its innovative cell therapy product for ovarian cancer, a breakthrough by founders like Alan Trounson and Bob Moses. 3️⃣ Zitcha: Lands $15m Series A led by VMG Partners, poised to expand operations to the US with backing from OIF Ventures. 4️⃣ 7 Kiwi startups: Share NZ$17.5m in grant funding, including diverse sectors like space, health, and cleantech, aiming for global impact. 5️⃣ OpenAI: Value skyrockets to $157bn after a $6.6bn funding round, attracting investment from top players like Thrive Capital and Microsoft. 6️⃣ ZBiotics: Raises $12m in Series A Funding to revolutionize the biotech industry with innovative GMO probiotic products. Get more insights into these exciting developments - read the full article for more: https://buff.ly/3YaHKZ6 📩 📩 📩 📩 📩 Stay ahead of the game! Join our free newsletter for daily startup insights: https://buff.ly/3QlzuB6 📩 📩 📩 📩 📩 \#StartupFunding \#InvestmentNews \#InnovationLeaders

In February, Y Combinator published their Request for Startups (RFS) for the first time since 2018. Interesting read! It included a call for “a way to end cancer", and more specifically startups that can reduce the cost of MRIs, given they are now highly sensitive in detecting cancer masses as small as a mm: "companies are already having success on a small scale offering MRIs to patients for a high cash price. However, there is backlash from the medical community as MRIs also create incidental findings (or false positives), that cost our healthcare system valuable time and money to investigate. For this to work, the world would need to scale up the number of MRI scans it does by at least 100x. Doing that will require innovations in the MRI hardware, the AI algorithms to interpret scans and reduce false positives, and the business models and consumer marketing to make it a viable business. We’re interested in funding companies looking to tackle this multifaceted problem." Surbhi Sarna Granza Bio (YC W24) responded to the call & caught my eye: They are advancing the delivery of cancer treatments through novel immunotherapy approaches.🌱 This emphasizes biotech's role in reshaping healthcare by tackling cancer from multiple angles. Closed $7 million seed funding from Felicis, Refactor, and Y Combinator. #Biotech

Titan Seed Fund team attends #BayOConnect 2024 Biotech conference in Munich! As part of our biotech investment strategy, the Titan Seed Fund team is participating in the #BayOConnect 2024 investment conference in Munich, Germany, organized by BioM Biotech Cluster Development GmbH. This event is hosting over 15 startups and many visionary researchers, innovative companies in the life science space from the Bavarian biotech landscape and beyond; such as Technical University of Munich, Roche, and the Max Planck Society . Our team will be meeting with world-class #biotech and #medtech #startups from across Europe. For our Titan Seed Fund, MEDIN is focused on backing AI-enabled technologies in fields such as #CRISPR, #Biomarker, #drug #manufacturing, #treatment, #cancer, #DigitalHealth, #tumor #therapy, #immunotherapy, … During the conference, we will be sharing the unique advantages of an investment from our Titan Seed Fund. Our portfolio startups gain the unique ability to tap into thousands of world-class Biotech and Medtech graduates, PhDs, #researchers, and #labs, by establishing R&D operations in Tunisia. If you are a founder attending #BayOConnect 2024 and want to learn more about our Deep Tech Fund and how we can help turbocharge your startup, drop us a comment below or meet us at the conference. About Titan Seed Fund: Titan Seed Fund is a deep tech VC fund focused on early-stage startups that are leveraging AI in two key sectors: (A) LifeSciences & Biotech, (B) SW, HW, IOT, Semis. We look for outstanding founders with heavy technical, research, and enterprise expertise, working to solve global problems through revolutionary technologies. Our fund invests in startups globally while enabling these startups to augment their R&D capabilities through our AI Cluster in Tunisia.

What does 'Investor Ready' mean to Ecphora Capital? Join Deborah Hemingway, PhD founder and Managing Partner of Ecphora Capital October 18th as she discusses how Ecphora Capital is de-risking and accelerating Maryland’s best biomedical startups. Sign up Today! #Biomedical #Investor #Biotech